Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Mol Sci ; 23(8)2022 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-35457197

RESUMEN

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is not restricted to the neuronal compartment but includes important interactions with immune cells, including microglia. Protein aggregates, common pathological hallmarks of AD, bind to pattern recognition receptors on microglia and trigger an inflammatory response, which contributes to disease progression and severity. In this context, curcumin is emerging as a potential drug candidate able to affect multiple key pathways implicated in AD, including neuroinflammation. Therefore, we studied the effect of curcumin and its structurally related analogues cur6 and cur16 on amyloid-ß (Aß)-induced microglia activation and neuronal cell death, as well as their effect on the modulation of Aß aggregation. Primary cortical microglia and neurons were exposed to two different populations of Aß42 oligomers (Aß42Os) where the oligomeric state had been assigned by capillary electrophoresis and ultrafiltration. When stimulated with high molecular weight Aß42Os, microglia released proinflammatory cytokines that led to early neuronal cell death. The studied compounds exerted an anti-inflammatory effect on high molecular weight Aß42O-stimulated microglia and possibly inhibited microglia-mediated neuronal cell toxicity. Furthermore, the tested compounds demonstrated antioligomeric activity during the process of in vitro Aß42 aggregation. These findings could be investigated further and used for the optimization of multipotent candidate molecules for AD treatment.


Asunto(s)
Enfermedad de Alzheimer , Curcumina , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Muerte Celular , Curcumina/uso terapéutico , Humanos , Microglía/metabolismo , Fragmentos de Péptidos/metabolismo
2.
Electrophoresis ; 36(19): 2465-72, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26084573

RESUMEN

Free solution capillary electrophoresis with UV detection is here used to retrieve information on the conformational changes of wild-type ß2 -microglobulin and a series of naturally and artificially created variants known to have different stability and amyloidogenic potential. Under nondenaturing conditions, the resolution of at least two folding conformers at equilibrium is obtained and a third species is detected for the less stable isoforms. Partial denaturation by using chaotropic agents such as acetonitrile or trifluoroethanol reveals that the separated peaks are at equilibrium, as the presence of less structured species is either enhanced or induced at the expenses of the native form. Reproducible CE data allow to obtain an interesting semiquantitative correlation between the peak areas observed and the protein stability. Thermal unfolding over the range 25-42°C is induced inside the capillary for the two pathogenic proteins (wtß2 -microglobulin and D76N variant): the large differences observed upon small temperature variation draw attention on the robustness of analytical methods when dealing with proteins prone to misfolding and aggregation.


Asunto(s)
Amiloide/análisis , Amiloide/química , Electroforesis Capilar/métodos , Microglobulina beta-2/análisis , Microglobulina beta-2/química , Amiloide/metabolismo , Pliegue de Proteína , Isoformas de Proteínas/análisis , Isoformas de Proteínas/química , Isoformas de Proteínas/metabolismo , Estabilidad Proteica , Proteínas Recombinantes/análisis , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Microglobulina beta-2/metabolismo
3.
ACS Chem Neurosci ; 10(3): 1420-1433, 2019 03 20.
Artículo en Inglés | MEDLINE | ID: mdl-30556996

RESUMEN

Alzheimer's disease is likely to be caused by copathogenic factors including aggregation of Aß peptides into oligomers and fibrils, neuroinflammation, and oxidative stress. To date, no effective treatments are available, and because of the multifactorial nature of the disease, it emerges the need to act on different and simultaneous fronts. Despite the multiple biological activities ascribed to curcumin as neuroprotector, its poor bioavailability and toxicity limit the success in clinical outcomes. To tackle Alzheimer's disease on these aspects, the curcumin template was suitably modified and a small set of analogues was attained. In particular, derivative 1 turned out to be less toxic than curcumin. As evidenced by capillary electrophoresis and transmission electron microscopy studies, 1 proved to inhibit the formation of large toxic Aß oligomers, by shifting the equilibrium toward smaller nontoxic assemblies and to limit the formation of insoluble fibrils. These findings were supported by molecular docking and steered molecular dynamics simulations which confirmed the superior capacity of 1 to bind Aß structures of different complexity. Remarkably, 1 also showed in vitro anti-inflammatory and antioxidant properties. In summary, the curcumin-based analogue 1 emerged as multipotent compound worthy to be further investigated and exploited in the Alzheimer's disease multitarget context.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/toxicidad , Curcumina/análogos & derivados , Curcumina/metabolismo , Mediadores de Inflamación/metabolismo , Fragmentos de Péptidos/toxicidad , Prenilación/fisiología , Enfermedad de Alzheimer/inducido químicamente , Enfermedad de Alzheimer/tratamiento farmacológico , Animales , Animales Recién Nacidos , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/uso terapéutico , Células Cultivadas , Curcumina/uso terapéutico , Relación Dosis-Respuesta a Droga , Humanos , Mediadores de Inflamación/antagonistas & inhibidores , Simulación del Acoplamiento Molecular/métodos , Prenilación/efectos de los fármacos , Estructura Secundaria de Proteína , Estructura Terciaria de Proteína , Ratas , Ratas Sprague-Dawley
4.
Talanta ; 188: 17-26, 2018 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-30029360

RESUMEN

Despite great efforts, it is not known which oligomeric population of amyloid beta (Aß) peptides is the main neurotoxic mediator in Alzheimer's disease. In vitro and in vivo experiments are challenging, mainly because of the high aggregation tendency of Aß (in particular of Aß 1-42 peptide), as well as because of the dynamic and non covalent nature of the prefibrillar aggregates. As a step forward in these studies, an analytical platform is here proposed for the identification and characterization of Aß 1-42 oligomeric populations resulting from three different sample preparation protocols. To preserve the transient nature of aggregates, capillary electrophoresis is employed for monitoring the oligomerization process in solution until fibril precipitation, which is probed by transmission electron microscopy. Based on characterization studies by ultrafiltration and SDS-PAGE/Western Blot, we find that low molecular weight oligomers build up over time and form bigger aggregates (> dodecamers) and that the kinetics strongly depends on sample preparations. The use of phosphate buffer results to be more aggregating, since trimers are the smallest species found in solution, whereas monomers and dimers are obtained by solubilizing Aß 1-42 in a basic mixture. For the first time, attenuated total reflection-Fourier transform infrared spectroscopy is used to assign secondary structure to the separated oligomers. Random coil and/or α-helix are most abundant in smaller species, whereas ß-sheet is the predominant conformation in bigger aggregates, which in turn are demonstrated to be responsible for Aß 1-42 toxicity.


Asunto(s)
Péptidos beta-Amiloides/química , Péptidos beta-Amiloides/toxicidad , Fragmentos de Péptidos/química , Fragmentos de Péptidos/toxicidad , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Dimetilsulfóxido/química , Electroforesis Capilar/métodos , Humanos , Fosfatos/química , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Multimerización de Proteína/efectos de los fármacos , Solventes/química , Espectroscopía Infrarroja por Transformada de Fourier/métodos
5.
J Alzheimers Dis ; 59(4): 1213-1226, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28731438

RESUMEN

BACKGROUND: Identifying physiologically relevant binding partners of amyloid-ß (Aß) that modulate in vivo fibril formation may yield new insights into Alzheimer's disease (AD) etiology. Human cathelicidin peptide, LL-37, is an innate immune effector and modulator, ubiquitous in human tissues and expressed in myriad cell types. OBJECTIVE: We present in vitro experimental evidence and discuss findings supporting a novel hypothesis that LL-37 binds to Aß42 and can modulate Aß fibril formation. METHODS: Specific interactions between LL-37 and Aß (with Aß in different aggregation states, assessed by capillary electrophoresis) were demonstrated by surface plasmon resonance imaging (SPRi). Morphological and structural changes were investigated by transmission electron microscopy (TEM) and circular dichroism (CD) spectroscopy. Neuroinflammatory and cytotoxic effects of LL-37 alone, Aß42 alone, and LL-37/Aß complexes were evaluated in human microglia and neuroblastoma cell lines (SH-SY5Y). RESULTS: SPRi shows binding specificity between LL-37 and Aß, while TEM shows that LL-37 inhibits Aß42 fibril formation, particularly Aß's ability to form long, straight fibrils characteristic of AD. CD reveals that LL-37 prevents Aß42 from adopting its typical ß-type secondary structure. Microglia-mediated toxicities of LL-37 and Aß42 to neurons are greatly attenuated when the two peptides are co-incubated prior to addition. We discuss the complementary biophysical characteristics and AD-related biological activities of these two peptides. CONCLUSION: Based on this body of evidence, we propose that LL-37 and Aß42 may be natural binding partners, which implies that balanced (or unbalanced) spatiotemporal expression of the two peptides could impact AD initiation and progression.


Asunto(s)
Péptidos beta-Amiloides/metabolismo , Péptidos beta-Amiloides/farmacología , Amiloide/química , Interleucina-1/farmacología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Amiloide/metabolismo , Amiloide/ultraestructura , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular , Células Cultivadas , Dicroismo Circular , Técnicas de Cocultivo , Humanos , Interleucina-6/metabolismo , Microglía/efectos de los fármacos , Microglía/metabolismo , Microglía/ultraestructura , Microscopía Electrónica de Transmisión , Neuroblastoma/patología , Unión Proteica/efectos de los fármacos , Estructura Secundaria de Proteína , Resonancia por Plasmón de Superficie , Lóbulo Temporal/citología , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA